Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions
International Journal of Molecular Sciences · 23.07.2025 · 26 (15) · 7119
DOI: 10.3390/ijms26157119 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.07.2025. Verfasst von Fátima Postigo-Corrales und 6 weiteren Autor:innen. Beteiligte Einrichtung: Health Sciences Faculty, Universidad Católica de Murcia (UCAM), 30107 Guadalupe, Spain. Hauptthemen laut MEDLINE: Docetaxel, Antineoplastic Agents, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Católica San Antonio de Murcia, Project MEFASCINAS (Análisis de Eficacia de Terapias Anti Fascina para el Tratamiento del Cáncer de Mama Triple Negativo).
Abstract (Originalsprache)
Docetaxel is a chemotherapeutic agent widely used for breast cancer treatment; however, its efficacy is often limited by drug resistance and associated toxicity. This review examines the molecular mechanisms of docetaxel resistance in breast cancer and discusses research advances and future directions for overcoming this challenge. Key resistance mechanisms include alterations in drug targets (microtubules), increased drug efflux, suppression of apoptosis, activation of survival signalling pathways, epithelial-to-mesenchymal transition (EMT), and cancer stem cell enrichment. An evolutionary perspective distinguishes between intrinsic and acquired resistance, emphasising the need for adaptive therapeutic strategies. Recent advances in genomic profiling, non-coding RNA research, novel drug combinations, and biomarker-guided therapies have also been reviewed. Emerging approaches, such as targeting the tumour microenvironment, harnessing immunotherapy, and implementing adaptive dosing schedules, have been discussed. This review emphasises the understanding of resistance as a multifactorial phenomenon that requires multipronged interventions. Research has aimed to identify predictive biomarkers, develop targeted agents to reverse resistance, and design rational combination strategies to improve patient outcomes. Progress in deciphering and targeting docetaxel resistance mechanisms holds promise for enhancing treatment responses and extending survival in patients with breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Sciences Faculty, Universidad Católica de Murcia (UCAM), 30107 Guadalupe, Spain.
- Group of Molecular Pathology and Pharmacogenetics, Pathology and Clinical Analysis Department, Instituto Murciano de Investigación Biosanitaria (IMIB), Hospital General Universitario Santa Lucía, 30202 Cartagena, Spain.
- Department of Medical Oncology, Morales Meseguer General University Hospital, 30008 Murcia, Spain.
ORCID-Profile: Asunción Beltrán-Videla, Antonio David Lázaro-Sánchez, Ana María Hurtado, Pablo Conesa-Zamora, Ana Belén Arroyo, Ginés Luengo-Gil
Förderung
- Universidad Católica San Antonio de Murcia
- Project MEFASCINAS (Análisis de Eficacia de Terapias Anti Fascina para el Tratamiento del Cáncer de Mama Triple Negativo)
Zitieren
APA
Postigo-Corrales, F., Beltrán-Videla, A., Lázaro-Sánchez, A. D., Hurtado, A. M., Conesa-Zamora, P., Arroyo, A. B., & Luengo-Gil, G. (2025). Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions. International Journal of Molecular Sciences, 26(15), 7119. https://doi.org/10.3390/ijms26157119
Vancouver
Postigo-Corrales F, Beltrán-Videla A, Lázaro-Sánchez AD, Hurtado AM, Conesa-Zamora P, Arroyo AB, et al. Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions. International Journal of Molecular Sciences. 2025;26(15):7119. doi:10.3390/ijms26157119
BibTeX
@article{PostigoCorrales2025,
author = {Postigo-Corrales, Fátima and Beltrán-Videla, Asunción and Lázaro-Sánchez, Antonio David and Hurtado, Ana María and Conesa-Zamora, Pablo and Arroyo, Ana Belén and Luengo-Gil, Ginés},
title = {Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {15},
pages = {7119},
doi = {10.3390/ijms26157119}
}
EUVIMED